drugset / Trial / NCT04008394
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
Phase 1
Unknown
50 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan Bio-Raid Biotechnology Co, Ltd. China · collab
NaSingle-groupOpen-labelTreatment
Summary
The overall purpose of this study is to explore the safety and therapeutic effect of CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Refractory/Relapsed lymphocyte malignancies.
Timeline
- Start
- 2019-07-03
- Primary completion
- 2022-07-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD30 CAR T cells | Cell therapy | — | — |